Finance

Lists
CSL:ASX
CSL Ltd
A$175.35
-1.62%
(-2.89) 1D
Oct 2, 5:12:48 PM GMT+11  ·   AUD
All symbols
SymbolPriceChange% Change
Generating top insights for CSL...
Open
A$178.03
High
A$179.98
Low
A$174.67
Mkt. cap
84.15B
Avg. vol.
1.24M
Volume
1.05M
Dividend
1.62%
Quarterly dividend
A$0.71
Ex-dividend date
Sep 11, 2023
52-wk high
A$222.47
52-wk low
A$90.00
EPS
-A$7.66
Shares outstanding
479.88M
No. of employees
29K
Open
A$178.03
High
A$179.98
Low
A$174.67
Mkt. cap
84.15B
Avg. vol.
1.24M
Volume
1.05M
Dividend
1.62%
Quarterly dividend
A$0.71
Ex-dividend date
Sep 11, 2023
52-wk high
A$222.47
52-wk low
A$90.00
EPS
-A$7.66
Shares outstanding
479.88M
No. of employees
29K
News stories
From web sources and news partners
The Motley Fool Australia
The Motley Fool Australia
·
20 hours ago
Top ASX shares to buy in October 2026
Profile
CSL Limited is an Australian multinational specialty biotechnology company that researches, develops, manufactures, and markets products to treat and prevent serious human medical conditions. CSL's product areas include blood plasma derivatives, vaccines, antivenom, and cell culture reagents used in various medical and genetic research and manufacturing applications. The company was established in 1916 as Commonwealth Serum Laboratories and was wholly owned by the Australian federal government until its privatisation in 1994. Wikipedia
About CSL Ltd
CEOPaul McKenzie
Employees29K
Founded1916
HeadquartersMelbourne, Victoria, Australia
SectorBiotechnology
Websitecsl.com
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
4.17B
4.17B
3.73B
3.73B
Cost of goods sold
1.94B
1.94B
1.93B
1.93B
Cost of revenue
1.94B
1.94B
1.93B
1.93B
Research and development expenses
300.00M
300.00M
311.50M
311.50M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
612.50M
612.50M
693.00M
693.00M
Operating expense
912.50M
912.50M
1.00B
1.00B
Total operating expenses
2.85B
2.85B
2.93B
2.93B
Operating income
1.32B
1.32B
802.00M
802.00M
Other non operating income
-
-
-
-
EBT including unusual items
190.00M
190.00M
-2.23B
-2.23B
EBT excluding unusual items
1.22B
1.22B
699.50M
699.50M
Income tax expense
47.00M
47.00M
-597.50M
-597.50M
Effective tax rate
24.74%
24.74%
26.75%
26.75%
Other operating expenses
-
-
-
-
Net income
200.50M
200.50M
-1.49B
-1.49B
Net profit margin
4.81%
4.81%
-39.92%
-39.92%
Earnings per share
-
-
-
-
Interest and investment income
9.00M
9.00M
6.00M
6.00M
Interest expense
-106.50M
-106.50M
-108.50M
-108.50M
Net interest expenses
-97.50M
-97.50M
-102.50M
-102.50M
Depreciation and amortization charges
-
-
-
-
EBITDA
1.56B
1.56B
974.00M
974.00M
Gain or loss from assets sale
22.50M
22.50M
500.00K
500.00K
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps